NLRP3 Inflammasome Activation Among Patients During Acute Gout Flares

NCT05744297 | Unknown

• 1 other identifier: ActiNG
• Study Type: observational
• Target: 10
• Locations: 1 country
• Sites: 1

Brief Summary

Gout is a chronic joint disease associated with deposition of monosodium urate crystals, as a consequence of hyperuricemia. Gout is an intermittent flaring condition and acute gout flares are driven by NLRP3 inflammasome and IL1-beta production. However pathogenesis of acute gout flares remains poorly known in vivo in human. The aim of this study is to evaluate NLRP3 inflammasome activation in vivo in patients cells during acute gout flares.

Conditions

Gout Arthritis

Outcome Measures

Primary Outcomes (1)

• NLRP3 inflammasome activation in white blood cells.

  White blood cells will be isolated from blood sample and NLRP3 inflammasome activation will be assessed by flow cytometry.

  Patient admission at hospital

Secondary Outcomes (2)

• NLRP3 inflammasome activation in synovial cells.

  Patient admission at hospital

• Effects of NLRP3 inflammasome inhibitors on proportion of NLRP3 inflammasome activation in white blood cells/synovial cells

  up to 7 days after analysis of NLRP3 activity

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Study will be proposed to patients meeting study's criteria

You may qualify if:

• Hospitalization for acute gout flare confirmed by joint fluid analysis or Nijmegen score \> 8
• Aged \> 18

You may not qualify if:

• Gout treatment already started
• Inflammatory Arthritis other than Gout Arthritis
• Pregnant or breast feeding women
• Patient protected by law

Sponsors & Collaborators

• Centre Hospitalier Saint Joseph Saint Luc de Lyon: lead

Study Sites (1)

Centre Hospitalier Saint Joseph Saint Luc

Lyon, 69007, France

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood and synovial fluid obtained from remainder of samples collected during standard of care required during acute goute flare.

MeSH Terms

Conditions

Arthritis, Gouty

Condition Hierarchy (Ancestors)

Gout; Arthritis; Joint Diseases; Musculoskeletal Diseases; Crystal Arthropathies; Rheumatic Diseases; Purine-Pyrimidine Metabolism, Inborn Errors; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Metabolic Diseases; Nutritional and Metabolic Diseases

Central Study Contacts

Julien Seiller, MD

CONTACT

478 617 757; jseiller@chsjsl.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 1 Day
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 2, 2023
• First Posted: February 27, 2023
• Study Start: April 28, 2023
• Primary Completion: June 1, 2023
• Study Completion: October 1, 2023
• Last Updated: May 12, 2023

Record last verified: 2023-02

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)